Search

everythinglearnresearchcommunity

for

Search:↓

Topical aldactone is discussed for its effects on men's hair and muscles. The conversation explores its potential benefits and side effects compared to other treatments like Minoxidil, finasteride, and RU58841.

Adenosine is discussed as a potential treatment for hair loss, with mentions of its presence in certain shampoos and Minoxidilmax products. Users express interest in topical adenosine but are cautious about sourcing it from places like Amazon or Alibaba.

A 19-year-old transgender individual is experiencing worsening temple recession despite taking female hormones and 1.25mg finasteride. They are seeking advice on additional treatments to address hair loss.

Clascoterone 5% solution shows strong potential for hair growth, offering a new treatment for alopecia with minimal side effects. It blocks androgen receptors locally and may be available by late 2026 or early 2027.

PP405 is a promising experimental topical treatment for alopecia that reactivates dormant hair follicles by targeting cellular energy, with large-scale trials planned for 2026. While it shows potential, it cannot regenerate permanently destroyed follicles, making hair transplants the only guaranteed solution for advanced baldness currently.

A 22-year-old with high estradiol levels is considering starting finasteride for hair loss. They have an upcoming endocrinologist appointment to discuss whether they should proceed with the treatment.

A 30-year-old male with thinning hair and an itchy, oily scalp found that hydrocortisone cream eliminated dandruff and itching and seemed to thicken his hair. He avoided minoxidil and finasteride due to potential side effects and noted that Nizoral and Head & Shoulders worsened his symptoms.

OP is considering Bicalutamide for female AGA and TE but is concerned about its side effects and effectiveness compared to Finasteride. OP is also using Minoxidil and Spironolactone but is experiencing significant shedding and is unsure if it's androgen-driven or due to Minoxidil changes.

Clascoterone shows promising results for hair regrowth in men with androgenetic alopecia, with potential FDA approval by 2026. It acts as a topical androgen receptor blocker, offering a new treatment option with minimal side effects compared to existing treatments like finasteride.

A 15-year-old is experiencing uneven hair loss, with one temple receding significantly. They are considering using finasteride, minoxidil, or dutasteride to slow hair loss before visiting a dermatologist, and may consider a hair transplant in the future.

The user is experiencing diffuse hair loss due to high testosterone levels and has tried various treatments including finasteride, minoxidil, nanoxidil, keto/caffeine shampoo, dermarolling, and RU-58841 with limited success. They are seeking advice on safely lowering testosterone levels to manage hair loss.

A user diagnosed with lymphoma is advised to stop finasteride during chemotherapy, with suggestions to consider treatments like Dutasteride and Minoxidil post-recovery. The focus is on prioritizing health over hair loss, with encouragement and advice from others who have experienced similar situations.

The user is experiencing hair loss and confusion over conflicting medical advice, with treatments including minoxidil, finasteride, and topical corticosteroids. They are unsure about the necessity of a biopsy and the timing of using minoxidil, while also considering the impact of potential androgenetic alopecia and telogen effluvium.

The conversation discusses hair loss treatments, focusing on the use of Minoxidil, finasteride, and triamcinolone. Concerns are raised about high concentrations of Minoxidil and the long-term use of corticosteroids.

Hydrocortisone helps relieve scalp itchiness, possibly caused by minoxidil. Users discuss its effectiveness for managing this side effect.

The conversation is about a user dealing with androgenetic alopecia using minoxidil 5% and attempting to import Adenogen tonic from Japan, which was rejected by Spanish customs. The user seeks advice on obtaining Adenogen or Adenovital within the EU or tips for passing customs.

The post discusses using a combination of Dutasteride, Minoxidil, Ketoconazole, Estradiol, and Spironolactone for hair regrowth. Users suggest it needs more time and possibly a transplant, with some sharing personal experiences and side effects of similar treatments.

The conversation discusses using topical cetirizine as a treatment for androgenetic alopecia (hair loss). Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

Clascoterone, a topical anti-androgen for hair loss, is expected to be released in late 2026 or early 2027.

OP believes RU58841 affected their thyroid, causing hypothyroidism and impacting minoxidil's effectiveness. They plan to start thyroid medication to improve hair regrowth.

The conversation discusses using scalp antiandrogens like RU58841, pyrilutamide, or fluridil on the face to reduce sebum production, noting that clascoterone (winlevi) is an approved facial antiandrogen with underwhelming reviews.

The conversation discusses GT20029, a compound by Kintor Pharma that degrades androgen receptors and is in trials, with potential as a hair loss cure. Another promising treatment mentioned is an antibody that blocks prolactin and has shown positive results in macaques.

A 27-year-old male is experiencing a recurring pattern of hair loss after 5 months of using oral minoxidil and finasteride, despite initial success. He is considering using topical androgen receptor blockers like RU58841, pyrilutamide, or clascoterone to address potential androgen receptor hypersensitivity.

Clascoterone phase 3 results show promising improvements in hair count, but concerns about high costs and lack of detailed data remain. Users compare it to existing treatments like Minoxidil and Finasteride, expressing skepticism about its accessibility and effectiveness.

KX-826 (Pyrilutamide) being tested in the US for hair loss treatment and that they have found enough people to participate in phase II clinical trials. Other treatments discussed are Minoxidil, finasteride, and RU58841.

The user has tried various hair loss treatments, including topilutamide, alfatradiol, pyrilutamide, and topical spironolactone, but experienced headaches. They are inquiring about the availability and legality of clascoterone in Spain.

A 26-year-old male considering a hair transplant is using topical finasteride and minoxidil, planning to start feminizing hormone replacement therapy (HRT) with estrogen and spironolactone. Many suggest waiting to see the effects of HRT, which may significantly regrow hair, before deciding on a transplant, and recommend adding microneedling and possibly switching to oral treatments for better results.

The user is experiencing ongoing hair loss despite using a comprehensive treatment regimen including dutasteride, oral minoxidil, cyproterone acetate, transdermal estradiol, and topical bicalutamide. They suspect cyproterone acetate may be worsening their hair loss and are considering switching to injection monotherapy.

The clinic diagnosed the user with NW3 and AGA, noting thinning hair despite using finasteride for 3 years, and suggested PRP and Mesotherapy before considering a transplant. The user questions the necessity of these treatments without confirming retrograde alopecia and its treatability.

Pyrilutamide, a nonsteroidal antiandrogen drug under development for the potential treatment of androgenic alopecia. The conversation discusses its binding affinity to the androgen receptor and the timeline for possible availability after trials are completed in the United States and China.